Clare J. Lee

3.5k total citations · 2 hit papers
61 papers, 2.3k citations indexed

About

Clare J. Lee is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Surgery. According to data from OpenAlex, Clare J. Lee has authored 61 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Physiology and 20 papers in Surgery. Recurrent topics in Clare J. Lee's work include Diabetes Treatment and Management (28 papers), Diet and metabolism studies (18 papers) and Bariatric Surgery and Outcomes (17 papers). Clare J. Lee is often cited by papers focused on Diabetes Treatment and Management (28 papers), Diet and metabolism studies (18 papers) and Bariatric Surgery and Outcomes (17 papers). Clare J. Lee collaborates with scholars based in United States, United Kingdom and Singapore. Clare J. Lee's co-authors include Nisa M. Maruthur, Cynthia L. Sears, Jeanne M. Clark, Vivian T. Thieu, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Julio Rosenstock, Carol Wysham and Shizuka Kaneko and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Clare J. Lee

52 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

2021 648 citations Juan P. Frías, Clare J. Lee et al. The Lancet profile →
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

2025 95 citations Deborah B. Horn, Beverly L. Falcón et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clare J. Lee United States	21	1.2k	776	688	563	396	61	2.3k
Kaj Stenlöf Sweden	26	1.6k 1.3×	1.2k 1.5×	953 1.4×	674 1.2×	433 1.1×	47	3.2k
A. Avignon France	28	930 0.8×	642 0.8×	497 0.7×	875 1.6×	112 0.3×	120	2.6k
Domenica Rubino United States	23	2.3k 1.9×	989 1.3×	567 0.8×	849 1.5×	1.6k 4.1×	60	3.4k
Christine Beebe United States	13	1.2k 1.0×	737 0.9×	524 0.8×	374 0.7×	168 0.4×	17	2.2k
L. Van Gaal Belgium	25	1.2k 1.0×	998 1.3×	456 0.7×	378 0.7×	632 1.6×	75	2.6k
Karl Nadolsky United States	8	840 0.7×	679 0.9×	424 0.6×	222 0.4×	517 1.3×	14	2.1k
Sam Dagogo‐Jack United States	15	1.2k 1.0×	351 0.5×	411 0.6×	537 1.0×	141 0.4×	40	1.8k
Karen R. Kelly United States	25	468 0.4×	903 1.2×	514 0.7×	547 1.0×	218 0.6×	71	2.2k
Andrés Acosta United States	38	1.1k 0.9×	1.5k 2.0×	1.9k 2.8×	580 1.0×	729 1.8×	151	4.4k
Raymond A Plodkowski United States	11	1.2k 1.0×	1.2k 1.6×	503 0.7×	259 0.5×	1.4k 3.6×	19	2.8k

Countries citing papers authored by Clare J. Lee

Since Specialization

Citations

This map shows the geographic impact of Clare J. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clare J. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clare J. Lee more than expected).

Fields of papers citing papers by Clare J. Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clare J. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clare J. Lee. The network helps show where Clare J. Lee may publish in the future.

Co-authorship network of co-authors of Clare J. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Clare J. Lee. A scholar is included among the top collaborators of Clare J. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clare J. Lee. Clare J. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Horn, Deborah B., Scott Kahan, Rachel L. Batterham, et al.. (2025). Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials. Clinical Obesity. 15(3). e12734–e12734. 3 indexed citations

Gourgari, Evgenia, Gitanjali Srivastava, Aaron S. Kelly, et al.. (2025). Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials. Obesity. 33(9). 1668–1679.

Hankosky, Emily R., Jérémie Lebrec, Clare J. Lee, et al.. (2025). Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT ‐1 trial. Diabetes Obesity and Metabolism. 27(12). 7385–7394. 1 indexed citations

Horn, Deborah B., Bruno Linetzky, Melanie J. Davies, et al.. (2025). Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity. JAMA Internal Medicine. 186(2). 157–157.

Hannon, Tamara S., Lily C. Chao, Margarita Barrientos‐Pérez, et al.. (2025). Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 406(10511). 1484–1496. 2 indexed citations

Ard, Jamy D., Clare J. Lee, Kimberly A. Gudzune, et al.. (2025). Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1. Diabetes Obesity and Metabolism. 27(9). 5064–5071. 3 indexed citations

Galindo, Rodolfo J., Clare J. Lee, Sheryl Allen, et al.. (2025). Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide. Diabetes Obesity and Metabolism. 27(10). 5694–5705. 1 indexed citations

Sattar, Naveed, et al.. (2024). Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2. Obesity Research & Clinical Practice. 18(5). S34–S35. 1 indexed citations

Gudzune, Kimberly A., et al.. (2024). #1696673 Weight reduction over time in tirzepatide-treated participants by early weight loss response – post hoc analysis in SURMOUNT-1. Endocrine Practice. 30(5). S66–S66. 2 indexed citations

10.

Block, Christophe De, Juan P. Frías, Clare J. Lee, et al.. (2024). Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2. Diabetologie und Stoffwechsel. 19(S 01). S78–S78. 1 indexed citations

11.

Shinde, Shraddha, et al.. (2024). Work loss among privately insured employees with overweight and obesity in the United States. Obesity Science & Practice. 10(4). e775–e775.

12.

Peters, Anne L., Raffaella Buzzetti, Clare J. Lee, et al.. (2024). Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS. The Journal of Clinical Endocrinology & Metabolism. 110(4). e962–e969. 4 indexed citations

13.

Zeitler, Philip, Rodolfo J. Galindo, Melanie J. Davies, et al.. (2024). Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care. 47(6). 1056–1064. 7 indexed citations

14.

Małecki, Maciej T., Rachel L. Batterham, Naveed Sattar, et al.. (2023). Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4. Diabetes Care. 46(12). 2292–2299. 26 indexed citations

15.

Boye, Kristina S., Vivian T. Thieu, Hélène Sapin, et al.. (2023). Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme. Diabetes Therapy. 14(11). 1833–1852. 10 indexed citations

16.

Shinde, Shraddha, et al.. (2023). SAT657 Work Loss Among Privately Insured Employees With Overweight And Obesity In The United States. Journal of the Endocrine Society. 7(Supplement_1). 1 indexed citations

17.

Al‐Sofiani, Mohammed E., Susan Langan, Alka M. Kanaya, et al.. (2020). The relationship of acculturation to cardiovascular disease risk factors among U.S. South Asians: Findings from the MASALA study. Diabetes Research and Clinical Practice. 161. 108052–108052. 31 indexed citations

18.

Varma, Sanskriti, Clare J. Lee, Todd T. Brown, et al.. (2019). Comparative Effects of Medical Versus Surgical Weight Loss on Body Composition: a Pilot Randomized Trial. Obesity Surgery. 29(8). 2503–2510. 10 indexed citations

19.

Lee, Clare J., Geetha Iyer, Yang Liu, et al.. (2017). The effect of vitamin D supplementation on glucose metabolism in type 2 diabetes mellitus: A systematic review and meta-analysis of intervention studies. Journal of Diabetes and its Complications. 31(7). 1115–1126. 90 indexed citations

20.

Lee, Clare J., et al.. (2016). Levothyroxine Dosing Following Bariatric Surgery. Obesity Surgery. 26(10). 2538–2542. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact